LFWD

Lifeward is a cash-crisis story that the filing states outright: management has 'concluded that there is substantial doubt as to our ability to continue as a going concern.' The balance sheet backs this up — cash and equivalents fell 67.8% to just $2.17M while operating cash flow ran at -$16.8M for FY2025. On that run-rate the company holds roughly six weeks of liquidity, so survival depends entirely on issuing more stock, not on operations. Stockholders' equity has already collapsed 55.4% to $8.41M against a -$285M accumulated deficit, and liabilities rose 24.5% to $14.5M (1.72x equity), so the cushion is thin and eroding.

The dilution machine is the whole thesis. The 10-K details a January 2025 placement of 151,515 shares at $33, a March ATM that sold 289,903 shares (avg $9.67, then $7.62 in Q4) for ~$2.8M gross, and a June securities purchase of 333,333 shares plus matching warrants at $7.80 — the offering price falling from $33 to $7.80 inside six months tells you how the market is pricing each raise. The share count shown down 85.6% reflects a reverse split, yet the company keeps issuing into a public float below $75M, which under Form S-3 rules caps primary raises at one-third of float per 12 months and forces reliance on the newly-effective 2026 $100M shelf. Every future dollar of survival capital comes at the current holder's expense, and there is $6.0M of non-cancelable purchase obligations due within a year sitting against $2.17M of cash.